• The CEO of CRISPR gave some encouraging business updates recently.
  • For risk-tolerant investors, the gene therapy’s stock is worth considering.
  • The company’s CEO’s recent statements are propelling the stock upward.

CRISPR Therapeutics (NASDAQ:CRSP) stock rose by around 9.3% on Tuesday, following a 3.9% increase on Monday. 

After the broader market started the week with a sell-off, Tuesday’s session saw a resurgence of growth stock momentum.


CRISPR CEO Sam Kulkarni’s comments added even more gains for his firm’s share price. Indeed, most biotech stocks gained ground Monday thanks in part to an interview given by Kulkarni at Cowen’s 42nd annual Health Care Conference.

Should investors buy CRISPR stock?

Positive clinical trials

At Cowen’s conference, Kulkarni offered an update on a beta-thalassemia and sickle cell disease therapy, a malignant tumor treatment, and other areas of the firm. He praised the efficacy of the first in clinical trials, suggesting that he was optimistic about the product. He also said that he believes the cancer treatment may be the first therapy in its field to go to market and generate $1 billion in annual sales.

Buying opportunity

Despite the positive news and Tuesday’s gain, CRISPR Therapeutics stock is still down by about 71% from its peak in January 2021, and the long retreat may have created a bargain buying opportunity for risk-tolerant investors.

Growth-dependent and otherwise speculative stocks were recently down amid many market factors, so investors should proceed with caution. In addition, CRISPR Therapeutics stock may experience more volatile swings in the near term due to various market pressures.


High risk, high reward

However, CRISPR Therapeutics stock is worth a deeper look based on the promise of the firm’s gene-editing-based therapies. This is a high-risk, high-reward bet with potential for big payoffs for patient investors, especially given its recent significant sell-offs.

(Visited 29 times, 1 visits today)